Rebeccamycin
Based on 1 Customer Validation
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.
For research use only. We do not sell to patients.
- CAS No.: 93908-02-2
- Formula: C27H21Cl2N3O7
- Molecular Weight:570.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
Topoisomerase I |
Traditional Cytotoxic Agents |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
|
[PMID: 11882002] |
| B16 | IC50 |
0.48 μM
Compound: 1
|
Inhibition of murine B16 Melanoma cell proliferation
Inhibition of murine B16 Melanoma cell proliferation
|
[PMID: 9341921] |
| B16 | IC50 |
0.48 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against murine B16 melanoma cells
Antiproliferative activity measured against murine B16 melanoma cells
|
[PMID: 9572888] |
| B16 | IC50 |
0.48 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity against B16 mouse melanoma cells
Antiproliferative activity against B16 mouse melanoma cells
|
[PMID: 8893841] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1
|
The cytotoxicity was evaluated in in HIV -I Lai infected CEM-SS cells.
The cytotoxicity was evaluated in in HIV -I Lai infected CEM-SS cells.
|
[PMID: 10346933] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against HIV-1 Lai infected CEM-SS cells
Cytotoxicity against HIV-1 Lai infected CEM-SS cells
|
[PMID: 10052965] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxic concentration is tested against CEM-SS cells
Cytotoxic concentration is tested against CEM-SS cells
|
[PMID: 9572888] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1 (Rebeccamycin)
|
Anti-HIV-1 activity in CEM-SS cells was measured by the quantification of the reverse transcriptase activity, associated with the virus particles released from HIV-1 infected cells in the culture medium.
Anti-HIV-1 activity in CEM-SS cells was measured by the quantification of the reverse transcriptase activity, associated with the virus particles released from HIV-1 infected cells in the culture medium.
|
[PMID: 10052965] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1
|
Compound was tested for anti-HIV activity in HIV -I Lai infected CEM-SS cells.
Compound was tested for anti-HIV activity in HIV -I Lai infected CEM-SS cells.
|
[PMID: 10346933] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1 (Rebeccamycin)
|
Inhibitory concentration is tested in HIV-1 Lai-infected CEM-SS cells
Inhibitory concentration is tested in HIV-1 Lai-infected CEM-SS cells
|
[PMID: 9572888] |
| HT-29 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line.
Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line.
|
[PMID: 11882002] |
| HT-29 | IC50 |
0.3 μM
Compound: Rebeccamycin
|
In vitro antiproliferative activity against human colon carcinoma HT-29 cells
In vitro antiproliferative activity against human colon carcinoma HT-29 cells
|
[PMID: 15743184] |
| K562 | IC50 |
0.2 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against K-562 (human leukemia) cell line.
Antiproliferative activity in vitro against K-562 (human leukemia) cell line.
|
[PMID: 11882002] |
| K562 | IC50 |
4 μM
Compound: Reb
|
Anticancer activity against human K562 cells
Anticancer activity against human K562 cells
|
[PMID: 18653350] |
| K562 | IC50 |
6 μM
Compound: Rebeccamycin
|
Inhibitory concentration against K5662 leukemia cell line in MTS assay
Inhibitory concentration against K5662 leukemia cell line in MTS assay
|
[PMID: 15801850] |
| L1210 | IC50 |
0.1 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line.
Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line.
|
[PMID: 11882002] |
| L1210 | IC50 |
0.14 μM
Compound: Rebeccamycin
|
Cytotoxicity activity against mouse L1210 cells by MTT assay
Cytotoxicity activity against mouse L1210 cells by MTT assay
|
[PMID: 20566289] |
| L1210 | IC50 |
0.14 μM
Compound: Rebeccamycin
|
In vitro antiproliferative activity against murine leukemia L1210 cells
In vitro antiproliferative activity against murine leukemia L1210 cells
|
[PMID: 15743184] |
| P388 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity against P388 Murine Leukemia cells
Antiproliferative activity against P388 Murine Leukemia cells
|
[PMID: 8893841] |
| P388 | IC50 |
0.5 μM
Compound: 1
|
Inhibition of P388 murine leukemia cell proliferation
Inhibition of P388 murine leukemia cell proliferation
|
[PMID: 9341921] |
| P388 | IC50 |
1.22 μM
Compound: 1
|
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
|
[PMID: 10346933] |
| P388 | IC50 |
1.22 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against P388 leukemia cells
Cytotoxicity against P388 leukemia cells
|
[PMID: 10052965] |
| P388 | IC50 |
1.22 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against P388 Leukemia cells
Antiproliferative activity measured against P388 Leukemia cells
|
[PMID: 9572888] |
| P388 | IC50 |
10.5 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against P388/CPT5 leukemia cells.
Cytotoxicity against P388/CPT5 leukemia cells.
|
[PMID: 10052965] |
| P388CPT5 | IC50 |
10.5 μM
Compound: 1
|
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
|
[PMID: 10346933] |
| P388CPT5 | IC50 |
10.5 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against P388CPT5 cells resistant to Topoisomerase I inhibitor Camptothecin
Antiproliferative activity measured against P388CPT5 cells resistant to Topoisomerase I inhibitor Camptothecin
|
[PMID: 9572888] |
| SW-620 | IC50 |
4 μM
Compound: Reb
|
Anticancer activity against human SW620 cells
Anticancer activity against human SW620 cells
|
[PMID: 18653350] |
| SW-620 | IC50 |
4 μM
Compound: Rebeccamycin
|
Inhibitory concentration against SW620 colorectal carcinoma cell line in MTS assay
Inhibitory concentration against SW620 colorectal carcinoma cell line in MTS assay
|
[PMID: 15801850] |
In Vitro
Rebeccamycin is an antitumor antibiotic produced by the actinomycete Saccharotrix aerocolonigenes with activity against several human tumor cell lines, including A549 (lung adenocarcinoma), HCT-116 (colon carcinoma), and KB (nasopharyngeal carcinoma) [1].
Rebeccamycin shows antibacterial activity against several Gram-positive bacteria, including Staphylococcus aureus and Streptococcus faecalis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CDF1 mice (B16 melanoma, L1210 leukemia)[2]
-
Dosage:2, 4, 8, 16, 32, 64, 128, 256 mg/kg
-
Administration:I.p.; daily for 9 days
-
Result:Prolongation of survival of the mice at dose levels ranging from 8 to 256 mg/kg.
Chemical Information
-
CAS No. 93908-02-2
-
Appearance Solid
-
Molecular Weight 570.38
-
Formula C27H21Cl2N3O7
-
SMILES
O=C(N1)C(C2=C3N([C@@H]([C@@H]([C@@H](O)[C@@H]4OC)O)O[C@@H]4CO)C5=C2C=CC=C5Cl)=C(C(C6=CC=C7)=C3NC6=C7Cl)C1=O
-
Structure Classification
-
Initial Source
the mycelium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Merchant J, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002 Jul;8(7):2193-201. [Content Brief]
[2]. Bush JA, et al. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo). 1987 May;40(5):668-78. [Content Brief]
[3]. Sánchez C, et al. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives. Chem Biol. 2002 Apr;9(4):519-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)